Cubist Systematic Strategies, LLC Apellis Pharmaceuticals, Inc. Transaction History

Cubist Systematic Strategies, LLC

$15.8 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $856,550 - $1.12 Million	15,464 Added 71.83%	36,994 $2.17 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $794,461 - $1.39 Million	-21,391 Reduced 49.84%	21,530 $1.29 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $41,198 - $155,421	1,742 Added 4.23%	42,921 $1.63 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $1.59 Million - $1.93 Million	20,710 Added 101.18%	41,179 $3.75 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $953,650 - $1.37 Million	20,469 New	20,469 $1.35 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $624,446 - $971,826	13,951 New	13,951 $953,000
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $361,361 - $610,099	-10,304 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $567,111 - $865,541	-15,993 Reduced 60.82%	10,304 $524,000
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $232,056 - $371,108	-7,549 Reduced 22.3%	26,297 $1.24 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $856,026 - $1.9 Million	27,262 Added 414.06%	33,846 $1.12 Million
Q2 2021 Aug 16, 2021	SELL	$40.9 - $64.9 $607,242 - $963,570	-14,847 Reduced 69.28%	6,584 $416,000
Q1 2021 May 17, 2021	BUY	$40.8 - $57.39 $509,551 - $716,743	12,489 Added 139.67%	21,431 $920,000
Q4 2020 Feb 16, 2021	SELL	$30.79 - $57.2 $623,990 - $1.16 Million	-20,266 Reduced 69.39%	8,942 $511,000
Q3 2020 Nov 16, 2020	SELL	$25.89 - $33.65 $194,511 - $252,812	-7,513 Reduced 20.46%	29,208 $881,000
Q2 2020 Aug 14, 2020	BUY	$24.8 - $38.49 $262,805 - $407,878	10,597 Added 40.56%	36,721 $1.2 Million
Q1 2020 May 15, 2020	SELL	$17.91 - $44.33 $397,691 - $984,347	-22,205 Reduced 45.95%	26,124 $700,000
Q4 2019 Feb 14, 2020	BUY	$22.1 - $30.8 $658,469 - $917,686	29,795 Added 160.76%	48,329 $1.48 Million
Q3 2019 Nov 14, 2019	BUY	$24.09 - $32.18 $444,436 - $593,688	18,449 Added 21704.71%	18,534 $446,000
Q2 2019 Aug 14, 2019	SELL	$18.0 - $25.34 $225,324 - $317,206	-12,518 Reduced 99.33%	85 $2,000
Q1 2019 May 15, 2019	SELL	$12.81 - $19.82 $137,681 - $213,025	-10,748 Reduced 46.03%	12,603 $246,000
Q4 2018 Feb 14, 2019	BUY	$11.47 - $18.71 $267,835 - $436,897	23,351 New	23,351 $308,000

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

Wellington Management Group LLP Boston, MA

15.6M
Shares

$516 Million
0.08% of portfolio
Eco R1 Capital, LLC San Francisco, CA

11.9M
Shares

$394 Million
14.88% of portfolio
Avoro Capital Advisors LLC New York, NY

11.1M
Shares

$368 Million
4.82% of portfolio
Vanguard Group Inc Valley Forge, PA

9.82M
Shares

$325 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.8M
Shares

$192 Million
0.01% of portfolio

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.

Account